Contrasting Akcea Therapeutics (AKCA) & Its Peers

Akcea Therapeutics (NASDAQ: AKCA) is one of 101 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Akcea Therapeutics to related companies based on the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Akcea Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akcea Therapeutics N/A N/A N/A
Akcea Therapeutics Competitors -2,502.90% -65.13% -7.51%

Valuation and Earnings

This table compares Akcea Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Akcea Therapeutics N/A -$83.21 million -4.52
Akcea Therapeutics Competitors $8.17 billion $1.09 billion 94.79

Akcea Therapeutics’ rivals have higher revenue and earnings than Akcea Therapeutics. Akcea Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

0.5% of Akcea Therapeutics shares are owned by institutional investors. Comparatively, 43.3% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Akcea Therapeutics and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akcea Therapeutics 0 0 4 0 3.00
Akcea Therapeutics Competitors 842 3721 6540 178 2.54

Akcea Therapeutics presently has a consensus price target of $24.00, indicating a potential upside of 34.83%. As a group, “Pharmaceuticals” companies have a potential upside of 23.88%. Given Akcea Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Akcea Therapeutics is more favorable than its rivals.

Summary

Akcea Therapeutics beats its rivals on 6 of the 11 factors compared.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company’s volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company’s clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply